Ker Yu
Overview
Explore the profile of Ker Yu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
71
Citations
1564
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Xue Y, Wang Y, Ren Z, Yu K
Oncogene
. 2024 Dec;
44(11):739-752.
PMID: 39658648
Pancreatic ductal adenocarcinoma (PDAC) remains the most challenging human malignancy that urgently needs effective therapy. Tissue factor (TF) is expressed in ~80% of PDAC and represents a potential therapeutic target....
2.
Jiang X, Yuan Z, Ding T, Yu K, Dong J
Int Immunopharmacol
. 2024 Sep;
142(Pt A):113111.
PMID: 39255679
The massive infiltration of suppressor immune cells within the tumor microenvironment (TME) of pancreatic ductal adenocarcinoma (PDAC) is a major cause of treatment resistance. Reducing this infiltration may represent a...
3.
Zhang Y, Liu L, Pei J, Ren Z, Deng Y, Yu K
Oncogene
. 2024 Jan;
43(9):668-681.
PMID: 38191673
The recently approved KRAS mutation-specific inhibitors sotorasib and adagrasib (KRAS-I) represent a promising therapy for KRAS-driven non-small cell lung cancer (NSCLC). However, many eligible patients do not benefit due to...
4.
Ren Z, Xue Y, Liu L, Zhang X, Pei J, Zhang Y, et al.
Cancer Lett
. 2023 May;
565:216221.
PMID: 37192729
Triple-negative breast cancer (TNBC) remains a most deadly human malignancy with limited response to chemotherapy, targeted therapy and immunotherapy. Tumor immunoenvironment plays an increasingly important role in therapy outcome. Tissue...
5.
Pei J, Wang Y, Ma L, Wang X, Liu L, Zhang Y, et al.
Acta Pharmacol Sin
. 2023 Jan;
44(6):1290-1303.
PMID: 36650292
The receptor tyrosine kinase AXL is an emerging driver of cancer recurrence, while its molecular mechanism remains unclear. In this study we investigated how AXL regulated the disease progression and...
6.
Lai M, Zhang T, Chen H, Song P, Tong L, Chen J, et al.
J Cancer
. 2023 Jan;
14(1):152-162.
PMID: 36605493
Osimertinib (AZD9291), a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI), has significantly improved the survival of non-small cell lung cancer (NSCLC) patients with EGFR mutation, the major...
7.
He S, Gu X, Yang J, Xu F, Hu J, Wang W, et al.
Front Pharmacol
. 2022 Nov;
13:902016.
PMID: 36324684
Tumor-associated macrophages (TAMs) are one of the most abundant immune cells in the pancreatic cancer stroma and are related to the poor prognosis of pancreatic ductal adenocarcinoma (PDAC) patients. Therefore,...
8.
Xia L, Tian E, Yu M, Liu C, Shen L, Huang Y, et al.
J Exp Clin Cancer Res
. 2022 Apr;
41(1):155.
PMID: 35459193
Background: The overall response rate to checkpoint blockade remains unsatisfactory, partially due to the immune-suppressive tumor microenvironment. A retinoic acid-related orphan receptor γt (RORγt) agonist (LYC-55716) is currently used in...
9.
Xing Y, Ren Z, Jin R, Liu L, Pei J, Yu K
Acta Pharmacol Sin
. 2022 Jan;
43(9):2410-2418.
PMID: 35082394
Although chemotherapy and recently approved immunotherapies have improved treatment of triple-negative breast cancer (TNBC), the clinical outcome for this deadly disease remains unsatisfactory. We found that both cluster of differentiation...
10.
Liu Y, Lai M, Li S, Wang Y, Feng F, Zhang T, et al.
Cancer Sci
. 2021 Dec;
113(2):709-720.
PMID: 34855271
With the wide clinical use of the third-generation epidermal growth factor receptor (EGFR) inhibitor osimertinib for the treatment of EGFR-mutated non-small cell lung cancer (NSCLC), acquired resistance caused by EGFR...